within Pharmacolibrary.Drugs.C_CardiovascularSystem.C01D_VasodilatorsUsedInCardiacDiseases.C01DX22_Vericiguat;

model Vericiguat
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.93,
    Cl = 4.444444444444445e-07,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.0448,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0056500000000000005,
    Tlag = 60.0,
    Vdp = 0.0247,
    k12 = 7.472222222222222e-07,
    k21 = 7.472222222222222e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Vericiguat</td></tr><tr><td>ATC code:</td><td>C01DX22</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>44.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Vericiguat is a soluble guanylate cyclase (sGC) stimulator used in the treatment of symptomatic chronic heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and heart failure hospitalization. It is approved for use in several countries, including the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with chronic heart failure after oral administration of vericiguat at steady-state.</p><h4>References</h4><ol><li><p>Fritsch, A, et al., &amp; Becker, C (2024). Clinical Pharmacokinetic and Pharmacodynamic Profile of Vericiguat. <i>Clinical pharmacokinetics</i> 63(6) 751–771. DOI:<a href=\"https://doi.org/10.1007/s40262-024-01384-1\">10.1007/s40262-024-01384-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38916717/\">https://pubmed.ncbi.nlm.nih.gov/38916717</a></p></li><li><p>Pieske, B, et al., &amp; Gheorghiade, M (2014). Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). <i>European journal of heart failure</i> 16(9) 1026–1038. DOI:<a href=\"https://doi.org/10.1002/ejhf.135\">10.1002/ejhf.135</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25056511/\">https://pubmed.ncbi.nlm.nih.gov/25056511</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C01DX22 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Vericiguat;
